Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and
| Current Price | ₹67.05 |
|---|---|
| Market Cap | ₹198 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 8 |
| Return on Equity | 22.27% |
| 52-Week Range | ₹36.30 – ₹164.02 |
| Beta (1Y) | 1.67 |
Brooks Laboratories Ltd. is trading at ₹67.05, with a market capitalisation of ₹198 Cr.
Brooks Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Brooks Laboratories Ltd. has a P/E of 8 and a return on equity of 22.27%.